Cell counting market was valued at $10.2 billion in 2025 and is projected to reach $22.2 billion by 2035, growing at a CAGR of 8.1% from 2026 to 2035. Growth is driven by rising adoption of biopharmaceutical production, clinical diagnostics, and cell-based research workflows. Increasing demand for precision medicine and biologics manufacturing is further boosting the need for accurate and automated cell counting technologies. According to the India BioEconomy Report 2026 published by DBT, BIRAC, and ABLE, India’s biotechnology ecosystem is expanding rapidly, particularly in biopharma, diagnostics, and life sciences R&D. The report highlights growing investments in biotechnology-enabled healthcare infrastructure, laboratories, and clinical development platforms. This expansion is expected to accelerate demand for advanced analytical tools used in cell-based research and bioprocessing. Overall, the strengthening bioeconomy in India supports long-term growth in the cell counting and related life science tools market.

Cardiovascular devices market was valued at $72.0 billion in 2025 and is projected to reach $131.0 billion by 2035, growing at a CAGR of 6.20% during the forecast period (2026–2035). Market growth is driven by the increasing burden of cardiovascular diseases and rising adoption of advanced medical technologies. According to the World Health Organization (WHO), cardiovascular diseases remain the leading cause of death globally, accounting for nearly 19.8 million casualties annually, or about 32% of total global casualties. This growing disease burden is significantly increasing demand for interventional cardiology devices, cardiac rhythm management systems, and structural heart solutions across healthcare systems globally. Additionally, expanding access to minimally invasive procedures and implantable cardiac technologies is improving patient outcomes and supporting market expansion.

Cardiac arrest treatment market was valued at $13.5 billion in 2025 and is projected to reach $23.0 billion by 2035, expanding at a CAGR of 5.8% during the forecast period. Market growth is primarily driven by the rising incidence of sudden cardiac arrest and increasing deployment of emergency response infrastructure. According to the World Health Organization, cardiovascular diseases account for nearly 17.9 million deaths annually, with a significant portion linked to sudden cardiac arrest. This growing burden is increasing demand for defibrillators, emergency drugs, and ICU-based post-arrest care. Additionally, the expansion of emergency medical services (EMS) and public access defibrillation programs is strengthening treatment accessibility across both developed and emerging regions.

Breast cancer drugs market was valued at approximately $37.0 billion in 2025 and is projected to reach around $91.8 billion by 2035, expanding at a CAGR of 9.6% over the forecast period from 2026 to 2035. This steady expansion is primarily driven by the rising global prevalence of breast cancer, which continues to place a significant burden on healthcare systems worldwide. According to the American Cancer Society, breast cancer remains one of the most diagnosed cancers, leading to a sustained increase in demand for effective and advanced treatment options. The growing patient population is accelerating the adoption of targeted therapies, immunotherapies, and combination regimens, which offer improved efficacy and personalized treatment outcomes.

Bone Morphogenetic Protein (BMP) market is poised for steady growth, with valuations expected to rise from $452.6 million in 2025 to $772.2 million by 2035, reflecting a CAGR of 5.6%. This trajectory is fueled by the global rise in orthopedic disorders and a corresponding increase in surgical interventions. Clinical evidence from PubMed Central confirms that BMPs offer superior bone repair and spinal fusion outcomes compared to traditional grafts, effectively reshaping regenerative medicine. By significantly reducing recovery times and surgical complications, these biologics have become essential in complex healing procedures. Consequently, hospitals maintain their position as the primary end-users, driven by high procedural volumes and the infrastructure to support advanced bone-healing technologies

Bipolar disorder market was valued at $9.7 billion in 2025 and is projected to reach $15.5 billion by 2035, growing at a CAGR of 4.8% from 2026 to 2035. The rising global burden of mental health disorders primarily drives growth. According to the World Health Organization (September 2025), more than 1 billion people worldwide are living with mental health conditions, highlighting a substantial unmet need for treatment and care. This burden includes bipolar disorder, which affects around 37 million people globally, significantly driving demand for effective therapies. The increasing prevalence is pushing healthcare systems to expand mental health services and treatment access. Additionally, improved diagnosis rates and growing awareness are enabling earlier intervention and long-term disease management. Expanding access to pharmacotherapy is further accelerating market growth.

Anal fistula therapeutics market was valued at $1.31 billion in 2025 and is projected to reach $2.39 billion by 2035, growing at a CAGR of 6.2% during the forecast period (2026–2035). Market growth is driven by the increasing prevalence of gastrointestinal disorders and rising adoption of minimally invasive surgical procedures. According to PubMed Central, advancements in treatment strategies for Crohn’s disease highlighted the growing use of biologics and stem cell-based therapies to manage complications such as anal fistulas. The study emphasized improved patient outcomes through targeted therapies and minimally invasive approaches. These developments are expected to indirectly drive innovation and demand in the anal fistula therapeutics market, particularly in regenerative and biologic treatment segments.

Account-based analytics software market was valued at approximately $5.5 billion in 2025 and is anticipated to reach $16.2 billion by 2035, registering a CAGR of 11.4% over the forecast period. This growth is largely driven by the accelerating pace of digital transformation across industries. In particular, the pharmaceutical sector is increasingly adopting data-driven strategies to target healthcare providers (HCPs) and institutions more effectively. The rising need for precise account targeting, personalized engagement, and measurable ROI is further fueling demand. Additionally, advancements in AI-powered analytics and cloud-based platforms are enhancing decision-making capabilities. As a result, organizations are increasingly investing in account-based analytics solutions to improve marketing efficiency and sales outcomes.

3D food printing market was valued at $330.0 million in 2025 and is projected to reach $1,780.0 million by 2035, expanding at a CAGR of 18.5% over the forecast period. This growth is largely driven by increasing demand for personalized nutrition and the adoption of automation in food production across healthcare and foodservice sectors. Rising health concerns and the need for customized dietary solutions are further accelerating market expansion. According to the World Health Organization (WHO), over 422 million people worldwide are living with diabetes, highlighting the growing need for tailored nutritional intake. 3D food printing enables the development of precision-based, texture-modified, and nutrient-specific foods. Such capabilities make it highly suitable for clinical nutrition and elderly care applications. Additionally, ongoing research and technological advancements continue to strengthen its role in the future of food innovation.

Psoriasis drug market was valued at $27.50 billion in 2025 and is projected to reach $66.90 billion by 2035, growing at a CAGR of 10.37% during the forecast period (2026–2035). The increasing global burden of chronic autoimmune diseases and rising adoption of biologics are significantly driving market growth. According to the World Health Organization, psoriasis affects more than 125 million people globally, representing a substantial patient pool requiring long-term treatment. The disease is associated with systemic complications such as cardiovascular disorders and psoriatic arthritis, further increasing treatment demand. Biologics and targeted therapies are increasingly being adopted due to their superior efficacy in moderate-to-severe cases, while topical therapies continue to dominate mild cases, supporting balanced growth across treatment categories.